Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

Patent ExpiryapprovedKeytrudaPositive

AI Analysis

Summary

A Dutch court ruled in favor of Halozyme, barring Merck from selling subcutaneous Keytruda in several European countries in a patent dispute. Separately, Enliven is preparing to initiate an anticipated leukemia trial.

Outcome Details

Dutch court barred Merck from selling subcutaneous Keytruda in several European countries

Importance:7/10

Sentiment:

0.70

patentlitigationEuropesubcutaneousregulatory

Related Companies

$HALO $MRK

Read the original article

Published by BioPharma Dive on October 7, 2026 3:21 PM

Read Original